Drug Trial Radar · NCT06613763
A Study of RAY1225 in Participants With Impaired Kidney Function
Last checked: Nov 19, 2026Latest source record: Mar 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Sep 11, 2024
Primary completion
Jan 10, 2025
Study completion Jan 20, 2025
Sponsor
- Lead sponsor
- Guangdong Raynovent Biotech Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Sep 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess how fast RAY1225 gets into the blood stream and how long it takes the body to remove it in participants with impaired kidney function compared to healthy participants.
Conditions
- Kidney Impairment
Interventions
RAY1225Drug
Administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of RAY1225 From Time Zero to T (AUC[0-t])Time frame: Baseline through Day 43
- PK: Maximum Concentration of RAY1225Time frame: Baseline through Day 43
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.